- Home
- CGTX vs CLNN Comparison
CGTX vs CLNN Comparison
Compare CGTX & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- CLNN
- Stock Information
- Founded
- CGTX 2007
- CLNN 2012
- Country
- CGTX United States
- CLNN United States
- Employees
- CGTX N/A
- CLNN N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- CLNN Health Care
- Exchange
- CGTX Nasdaq
- CLNN Nasdaq
- Market Cap
- CGTX 23.1M
- CLNN 26.1M
- IPO Year
- CGTX 2021
- CLNN N/A
- Fundamental
- Price
- CGTX $0.28
- CLNN $2.75
- Analyst Decision
- CGTX Strong Buy
- CLNN Strong Buy
- Analyst Count
- CGTX 5
- CLNN 5
- Target Price
- CGTX $6.13
- CLNN $40.00
- AVG Volume (30 Days)
- CGTX 692.0K
- CLNN 62.6K
- Earning Date
- CGTX 05-07-2025
- CLNN 05-07-2025
- Dividend Yield
- CGTX N/A
- CLNN N/A
- EPS Growth
- CGTX N/A
- CLNN N/A
- EPS
- CGTX N/A
- CLNN N/A
- Revenue
- CGTX N/A
- CLNN $350,000.00
- Revenue This Year
- CGTX N/A
- CLNN N/A
- Revenue Next Year
- CGTX N/A
- CLNN $2,066.67
- P/E Ratio
- CGTX N/A
- CLNN N/A
- Revenue Growth
- CGTX N/A
- CLNN N/A
- 52 Week Low
- CGTX $0.31
- CLNN $2.55
- 52 Week High
- CGTX $2.95
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- CGTX 31.37
- CLNN 39.96
- Support Level
- CGTX $0.40
- CLNN $2.91
- Resistance Level
- CGTX $0.47
- CLNN $3.08
- Average True Range (ATR)
- CGTX 0.03
- CLNN 0.22
- MACD
- CGTX -0.01
- CLNN 0.00
- Stochastic Oscillator
- CGTX 2.76
- CLNN 21.28
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.